EPIX NASDAQ
ESSA Pharma Inc.
1W: -7.5%
1M: -1.9%
3M: -5.0%
1Y: -73.6%
3Y: -9.2%
5Y: -75.2%
$0.20
Last traded 2025-10-09 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$9.5M
52W Range0.18-6.45
Volume5,945,141
Avg Volume6,752,718
Beta1.53
Dividend—
Analyst Ratings
Company Info
CEODavid Ross Parkinson
Employees35
SectorHealthcare
IndustryBiotechnology
IPO Date2015-03-13
Websiteessapharma.com
999 West Broadway
Vancouver, BC V5Z 1K5
CA
Vancouver, BC V5Z 1K5
CA
17783310962
About ESSA Pharma Inc.
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Parkinson David Ross | D-Return | 65,675 | $0.12 | 2025-10-09 |
| Wood David S. | D-Return | 33,343 | $0.12 | 2025-10-09 |
| BERGER FRANKLIN M | D-Return | 784,404 | $0.12 | 2025-10-09 |
| Glickman Richard M | D-Return | 43,240 | $0.12 | 2025-10-09 |
| Requadt Scott | D-Return | 30,002 | $0.12 | 2025-10-09 |